[The effect of danazol and tamoxifen on endometrial hyperplasia].
Endometrial hyperplasia has been considered as a hormone dependent lesion. Besides atypical genital bleeding, the possibility of endometrial carcinoma is also of significance. In this study, we administered 400mg daily of Danazol in 29 cases or 20mg daily of tamoxifen in 20 cases, respectively, for climacteric or postmenopausal women with different types of endometrial hyperplasia, and discussed their effect. Genital bleeding due to hyperplasia disappeared within 10-28 days in the danazol group and within 7-30 days in the tamoxifen group. In the latter group also, 2 climacteric women experienced menopause. The tortuous gland of hyperplasia became smaller and rounder. At the end of the treatment the glandular epithelium was low and showed a very poor secretory phase. The nuclei mitosis both in the glandular and stromal cells disappeared. The regression of hyperplasia was obtained after 1, 3, 6 months of danazol therapy in 37.9%, 72.4%, 93.1% and with tamoxifen therapy in 65%, 80%, 90% respectively, without undesirable side effects. In conclusion, the control of the endometrial hyperplasia with danazol and tamoxifen was suggested, and the results of the use of the suggested method were no further occurrence and/or progression of the disease. Both of the drugs were effective and safe alternative therapy for endometrial hyperplasia to progesterone.
Soh
E
E
Dept. of Obstetrics and Gynecology, Toranomon Hospital, Tokyo, Japan.
D003613:Danazol / Q000627:therapeutic use*; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
D011245:Pregnadienes; D013629:Tamoxifen; D003613:Danazol